
Novartis Shareholder Demands Board Overhaul
Artisan Partners has called for a major board shake-up at Novartis following recent drug trial failures and disappointing acquisitions. The large shareholder criticized the company deal oversight after shares dropped significantly.
Xurve View
Insights:
Xurve View

A major shareholder in NOVARTIS AG-REG demanded a board shake-up after back-to-back trial setbacks erased nearly $30 billion from the company's market value. David Samra, managing director at ARTISAN PARTNERS ASSET MA -A, said the Swiss drugmaker must overhaul how it oversees acquisitions following recent failures. The pressure comes as the stock suffered a record fall during the Tuesday morning session in Zurich.








